Wire · opportunities
Hims & Hers down as FDA advisors snub first peptide
◆ Sectors
Digital Health
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 24 July 2026 · Fusion42 review
FDA advisory committee rejected Hims & Hers' peptide candidate, sending the telemedicine company's stock down. The negative decision signals regulatory hurdles for telehealth players moving into weight-loss and metabolic drug delivery.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building telehealth or direct-to-consumer pharma, the FDA is not rubber-stamping peptide approvals: advisory votes matter, and they just said no to one of the best-capitalised players in the space. Your clinical path is harder than the hype suggested.
◆ Coverage
1 source · 24 Jul 2026
◆ Related on Wire
◆ Topics
Digital Healthfda-rejectiontelehealthpeptide-drugsregulatory-riskweight-loss-market